Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARVN003
- Development stage
- Unknown
- Lead developer
- Hyperion DeFi
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
ARVN003 is a proprietary ophthalmic formulation of pilocarpine developed for the pharmacologic treatment of presbyopia. It utilizes the Optejet® microdosing platform, which delivers precise, small-volume doses to improve tolerability and usability compared to traditional eye drops. The mechanism involves pupil constriction (miosis), which increases depth of focus through a small aperture effect and temporarily enhances near vision in adults with presbyopia. ARVN003 is being developed by Arctic Vision under license from Eyenovia for Greater China and South Korea. In clinical trials (notably Phase III in China), it has demonstrated statistically significant improvements in distance-corrected near visual acuity with good tolerability[1][2][3][6][7][8][9].
- Brand names
- MicroLine
- Other names
- pilocarpine micro-formulationpilocarpine microdose ophthalmic solution
02
Targets
CHRM3 (M3)
Beyond the preview
Go deeper on ARVN003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARVN003.